ALPS Medical Breakthroughs ETF (SBIO)
Description
The investment seeks to track the performance of the S-Network Medical Breakthroughs Index. The SBIO ETF contains 126 constituents. It is focused on growth holdings in the North America region.
Price $28.98 as of 2022-10-20Cost/Risk/Yield
| Dividend yield | |
| Expense ratio | 0.5% |
| Average spread | 0.38% |
| 1Y roundtrip cost | 0.88% |
Historic prices
Total Returns (including dividends)
Monthly returns heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -17.6% | -3.4% | 0.1% | -15.3% | -9.8% | 7.8% | 7.8% | 6.1% | -4.8% | -3.8% | -33.1% | ||
| 2021 | 9.4% | -1.5% | -8.9% | -0.3% | -7.0% | 5.0% | -10.0% | 6.6% | -3.0% | 1.2% | -6.9% | -1.5% | -17.0% |
| 2020 | -6.0% | -3.2% | -17.6% | 20.3% | 8.8% | 0.8% | -4.5% | 3.7% | -0.7% | 6.1% | 12.4% | 4.4% | 24.6% |
| 2019 | 13.9% | 7.6% | 4.9% | -5.6% | -5.6% | 12.0% | -2.3% | -2.5% | -8.3% | 10.6% | 13.4% | 6.9% | 45.0% |
| 2018 | 8.9% | -3.6% | -0.5% | -0.8% | 12.6% | -2.6% | 0.6% | 3.2% | 1.7% | -14.4% | -0.4% | -13.8% | -9.1% |
| 2017 | 2.4% | 11.5% | -1.5% | 3.3% | -8.1% | 13.8% | 1.8% | 8.9% | 0.9% | -2.6% | 4.3% | 5.4% | 40.2% |
| 2016 | -28.1% | -8.0% | 4.4% | 7.3% | 7.9% | -10.8% | 11.0% | -4.1% | 8.3% | -16.4% | 10.6% | -5.1% | -23.0% |
| 2015 | 7.9% | 9.0% | 2.3% | -5.3% | 19.9% | 4.8% | 6.7% | -13.1% | -15.4% | 6.6% | 8.5% | -1.5% | 30.3% |
| -9.3% | 8.3% | -16.9% | 3.7% | 18.7% | 30.8% | 11.0% | 8.8% | -21.2% | -12.6% | 41.9% | -5.3% |
Historical Dividends
Monthly dividend heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | 0.02 | 0.02 | |||||||||||
| 2018 | 0.78 | 0.78 | |||||||||||
| 2017 | 0.58 | 0.58 | |||||||||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.38 |
Sectors and Top Holdings
| Security | % Assets |
|---|---|
| Legend Biotech Corporation Sponsored ADR | 4.45% |
| Kodiak Sciences, Inc. | 3.53% |
| Cerevel Therapeutics Holdings Inc | 3.45% |
| Vir Biotechnology, Inc. | 2.89% |
| Alkermes Plc | 2.87% |
| TG Therapeutics, Inc. | 2.61% |
| Aurinia Pharmaceuticals Inc. | 2.48% |
| Karuna Therapeutics, Inc. | 2.43% |
| Iovance Biotherapeutics Inc | 2.21% |
| Arena Pharmaceuticals, Inc. | 2.05% |
| Springworks Therapeutics, Inc. | 1.93% |
| Cytokinetics, Incorporated | 1.71% |
| ACADIA Pharmaceuticals Inc. | 1.69% |
| Amicus Therapeutics, Inc. | 1.64% |
| Agios Pharmaceuticals, Inc. | 1.62% |
| Top 15 Weights | 37.56% |
Compare with similar ETFs
| SBIO | FBT | IBBJ | JSMD | SPXZ | XBI | |
|---|---|---|---|---|---|---|
| Product name | ALPS Medical Breakthroughs ETF | First Trust NYSE Arca Biotechnology Index Fund | Defiance Nasdaq Junior Biotechnology ETF | Janus Small/Mid Cap Growth Alpha ETF | Morgan Creek - Exos SPAC Originated ETF | SPDR S&P Biotech ETF |
| Issuer | ALPS | First Trust | Defiance | Janus Henderson | Morgan Creek | SPDR |
| Price | $28.98 | $137.06 | $29.87 | $49.0431 | $11.005 | $76.72 |
| Expense Ratio | 0.5% |  0.55% |  0.45% | 0.3% | 1% | 0.35% |
| Average Spread | 0.380% | 0.117% | 0.301% | 0.347% | 0.363% | 0.039% |
| AUM | $131,281,000 | $1,460,230,000 | $7,270,600 | $143,499,000 | $10,689,600 | $4,235,320,000 |
| Shares | 4,530,063 | 10,653,924 | 243,408 | 2,925,980 | 971,338 | 55,204,877 |
| Average Daily Volume | 15,867 | 32,637 | 2,561 | 12,731 | 1,935 | 11,331,733 |
| Home page | Visit external site | Visit external site | Visit external site | Visit external site | Visit external site | Visit external site |
| Inception Date | 2014-12-31 | 2006-06-19 | 2020-08-03 | 2016-02-25 | 2021-01-20 | 2006-01-31 |
| Index Tracked | S-Network Medical Breakthroughs Index | NYSE Arca Biotechnology (TR) | NASDAQ Junior Biotechnology Index | Janus Small/Mid Cap Growth Alpha Index | No Underlying Index | S&P Biotechnology Select Industry Index |
| Category | Health & Biotech Equities | Health & Biotech Equities | Health & Biotech Equities | Mid Cap Growth Equities | Financials Equities | Health & Biotech Equities |
| Asset Class | Equity | Equity | Equity | Equity | Equity | Equity |
| Asset Class Size | Mid/Small Caps | Large/Mid Caps | Mid/Small Caps | Large/Mid/Small Caps | Mid/Small Caps | |
| Value or Growth | Growth | Growth | Growth | Growth | Growth | |
| Region | North America | North America | North America | North America | North America | North America |
| Countries | U.S. | U.S. | U.S. | U.S. | U.S. | U.S. |
| Annual Dividend Rate | $0 | $2.214 | $0 | $0.191 | $0 | $0 |
| Annual Dividend Yield | 0.000% | 0.016% | 0.000% | 0.004% | 0.000% | 0.000% |
| Number of Holdings | 126 | 31 | 231 | 259 | 0 | 196 |
| YTD Return | -31.39% | -15.37% | 0.00% | -27.48% | -30.55% | -31.48% |
| Beta | 1.30 | 1.20 | 0.51 | 1.17 | 0.26 | 1.42 |
| Upside Beta | 0.68 | 0.06 | 1.06 | 0.78 | -0.91 | 0.12 |
| Downside Beta | -0.34 | -0.13 | 0.62 | 0.00 | -0.80 | -0.15 |
| Volatility 1Y | 44.99% | 28.39% | 29.75% | 29.85% | 29.99% | 45.75% |
| Sharpe Ratio 3Y | -0.26 | 0.09 | 0.00 | 0.16 | 0.00 | -0.12 |
| Treynor Ratio 3Y | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |